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Ryanodine receptors are part of 
the myospryn complex in cardiac 
muscle
Matthew A. Benson1, Caroline L. Tinsley2, Adrian J. Waite  2, Francesca A. Carlisle2, Steve M. 
M. Sweet3, Elisabeth Ehler4, Christopher H. George5, F. Anthony Lai5,6, Enca Martin-Rendon7 
& Derek J. Blake  2
The Cardiomyopathy–associated gene 5 (Cmya5) encodes myospryn, a large tripartite motif (TRIM)-
related protein found predominantly in cardiac and skeletal muscle. Cmya5 is an expression biomarker 
for a number of diseases affecting striated muscle and may also be a schizophrenia risk gene. To further 
understand the function of myospryn in striated muscle, we searched for additional myospryn paralogs. 
Here we identify a novel muscle-expressed TRIM-related protein minispryn, encoded by Fsd2, that 
has extensive sequence similarity with the C-terminus of myospryn. Cmya5 and Fsd2 appear to have 
originated by a chromosomal duplication and are found within evolutionarily-conserved gene clusters 
on different chromosomes. Using immunoaffinity purification and mass spectrometry we show that 
minispryn co-purifies with myospryn and the major cardiac ryanodine receptor (RyR2) from heart. 
Accordingly, myospryn, minispryn and RyR2 co-localise at the junctional sarcoplasmic reticulum of 
isolated cardiomyocytes. Myospryn redistributes RyR2 into clusters when co-expressed in heterologous 
cells whereas minispryn lacks this activity. Together these data suggest a novel role for the myospryn 
complex in the assembly of ryanodine receptor clusters in striated muscle.
The unique cytoskeletal organisation of striated muscle is dependent upon the formation of specialised interac-
tions between proteins that have both structural and signalling functions1. For example, the sarcomere is organ-
ised around the 4 MDa protein titin; the largest protein in the vertebrate proteome, that spans half the length of 
the sarcomere from the Z-disc to the M-line. The Z-disc provides the framework for the assembly and anchoring 
of the numerous multi-protein complexes of the sarcomere and also integrates signal transduction events that are 
thought to mediate the stretch response2, 3. In addition to titin, striated muscle expresses a repertoire of very large 
proteins that interact with the unique structural elements of the sarcomere. Many of these enigmatic proteins 
including obscurin, nebulin and titin have a repeating, modular architecture and interact with a myriad of differ-
ent proteins in the myocyte and cardiomyocyte4–8.
Myospryn, encoded by the CMYA5 gene, is a similarly enigmatic 500 kDa protein that is expressed predom-
inantly in skeletal and cardiac muscle9, 10. Myospryn has greatest sequence similarity to the midline E3 ubiqui-
tin ligases that are members of the TRIM superfamily of proteins and has also been designated TRIM769, 11, 12. 
This similarity does not encompass the RING domain of the midline proteins potentially negating the possi-
bility that myospryn is an E3 ubiquitin ligase. While the function of myospryn in muscle is unknown, levels of 
its transcript are altered in diseases affecting striated muscle including Duchenne muscular dystrophy (DMD), 
experimentally-induced hypertrophy and cardiomyopathy13–16. Furthermore, heterozygous CMYA5 mutations 
have recently been identified by whole exome sequencing in Chinese patients with sporadic hypertrophic cardi-
omyopathy whereas CMYA5 polymorphisms are associated with left ventricular wall thickness in patients with 
hypertension17, 18. Myospryn expression is positively regulated in vivo by the transcription factor Mef2a and is 
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consequently down-regulated in Mef2a-deficient mice10. In addition to muscle disease, common CMYA5 genetic 
variants have also been associated with an increased risk of schizophrenia19, 20.
Myospryn was originally identified in a yeast two-hybrid screen for proteins interacting with dysbindin; a 
component of the biogenesis of lysosome-related organelles complex-1 (BLOC-1) endosomal trafficking com-
plex9. In addition to dysbindin, myospryn has been shown to interact with desmin21, α-actinin10, the RIIα regu-
latory subunit of PKA22, 23, dystrophin22, calcineurin24, titin and calpain-325. In spite of myospryn’s size, all of the 
currently identified myospryn interactors bind to overlapping regions in the C-terminus of the protein encom-
passing the tripartite motif15, 25, 26. For example, α-actinin, the regulatory subunit of protein kinase A (PKA, RIIα) 
and titin bind to overlapping sites within the C-terminus of myospryn that include the FN3 domains, the BBC 
domain and the SPRY domain10, 23, 25, 27. Similarly, calpain-3 and dysbindin bind to the region encompassing the 
BBOX’/BBC and first FN3 domains whereas desmin binds to the distal part of the SPRY domain at the extreme 
C-terminus of myospryn9, 21, 25.
Given the number of myospryn-binding proteins described to date, it is not surprising that its specific func-
tion(s) in striated muscle remains unresolved. Furthermore, the subcellular location of myospryn in muscle is far 
from clear. Myospryn has been shown to co-localise with α-actinin, dystrophin and the RIIα regulatory subunit 
of PKA at the costameres of skeletal muscle10, 22, 23. It has therefore been suggested that myospryn may be a costa-
meric A-kinase anchoring protein22, 23. By contrast, Sarparanta and colleagues showed that myospryn immu-
noreactivity flanked the Z-line and was also present at sites along the sarcomere including the M-band where 
it can interact with titin and calpain-325. In cardiac muscle myospryn is reported to be found predominantly at 
the intercalated discs and costameres co-localising with desmin and, at the perinuclear region and endoplasmic/
sarcoplasmic reticulum of cultured neonatal cardiomyocytes21.
To gain further insight into the function of myospryn in striated muscle we used a combination of biochemical 
and immunochemical techniques to find physiologically relevant myospryn-associated proteins. Using immuno-
affinity chromatography and mass spectrometry we show that myospryn exists as part of an oligomeric protein 
complex in cardiac muscle with the cardiac ryanodine receptor (RyR2). This complex also contains a previously 
unreported paralog of myospryn that we have named minispryn.
Results
Cloning and initial characterisation of minispryn. Previously we reported that myospryn has a BBOX’ 
domain required for binding to dysbindin9. To find other proteins that have a similar architecture, we searched 
the NCBI (National Center for Biotechnology Information) databases for myospryn paralogs that contained 
this sequence. This search identified a single expressed sequence tag (EST, srf30) that was predicted to encode a 
BBOX’-containing protein9. A PCR product spanning the EST was used to screen a skeletal muscle cDNA library 
for full-length cDNA clones, thus yielding mini7E. The full-length sequence of mini7E is 6148 bp and has a sin-
gle large open reading frame that encodes a 716 amino acid protein with a predicted molecular mass of 81 kDa 
(Supplementary Fig. S1). Based upon its size and paralogy with myospryn (see below), we have named this pro-
tein minispryn. The NCBI annotation for the genes encoding minispryn and myospryn are Fsd2 (fibronectin type 
III and SPRY domain containing 2, Gene ID: 244091) and Cmya5 (Gene ID: 76469) respectively. For convenience, 
in this manuscript we have used the names Fsd2 and Cmya5 to describe the gene, and minispryn and myospryn 
to describe their respective cognate proteins.
Minispryn shares 45.5% protein sequence similarity with the C-terminus of myospryn retaining the same 
domain architecture and order; BBOX’, BBC, two FN3 domains and a C-terminal SPRY domain (Fig. 1a). By con-
trast, minispryn lacks the large N-terminal region that constitutes the majority of the myospryn protein including 
the low complexity repeat region9. Other than myospryn, the closest vertebrate minispryn homologs are the 
midline proteins encoded by the MID1 and MID2 genes and the Muscle Ring Finger (MuRF) proteins (Fig. 1b). 
The midline and MuRF proteins contain the canonical RING, BBOX and BBC domains found in the majority 
of the TRIM family of E3-ubiquitin ligases11. By contrast, minispryn and myospryn only contain the C-terminal 
domains that follow the BBOX of the midline proteins and are thus devoid of an apparent RING-domain 
(Fig. 1b). Furthermore, minispryn and myospryn have tandem FN3 domains whereas the midline proteins only 
have a single FN3 domain.
Comparison of the genomic organization of Fsd2 and Cmya5 shows that the architecture of each gene is 
remarkably similar, both being composed of 13 exons (Supplementary Fig. S2A). The difference in size of the 
two proteins is attributable to the sequence encoded by exon 2, which in Cmya5 is 9.3 kb but only 582 bp in Fsd2. 
Long-range sequence analysis around the CMYA5 and FSD2 loci showed that each gene is contained within a 
conserved chromosomal duplication (Supplementary Fig. S2B). The CMYA5 cluster that contains the HOMER1, 
JMY and AP3B1 genes spans approximately 2.5 Mbp of chromosome 5 whereas the FSD2 cluster on chromosome 
15 that contains HOMER2, WHAMM (JMY paralog) and AP3B2 spans only 240 kb. The genomic architecture 
of the CMYA5 and FSD2 clusters is also conserved in teleost fish species such as Tetraodon that diverged from a 
common ancestor approximately 450 million years ago.
Minispryn transcript and protein. Northern blot analysis shows that the 7 kb minispryn transcript is 
expressed at highest levels in heart but is also detectable in skeletal muscle (Fig. 2a). An anti-minispryn antibody 
(819) was raised in rabbits against the first 227 amino acids of minispryn. The specificity of the anti-myospryn 
and anti-minispryn antibodies was determined by immunoblotting extracts prepared from HEK293T cells 
over-expressing untagged myospryn and minispryn. Each antibody detects its cognate antigen and does not 
cross-react with their respective paralog (Fig. 2b). The tissue distribution of minispryn in the adult mouse was 
confirmed with the anti-minispryn antibody that detects a protein of approximately 90 kDa in cardiac and skeletal 
muscle (Fig. 2c). We used publically available expression data to examine the relative abundance of the transcripts 
encoding minispryn and myospryn in heart and skeletal muscle28. FSD2 was expressed at relatively low levels in 
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heart (6.3 RPKM (Reads Per Kb of transcript per Million mapped reads)) and skeletal muscle (5.6 RPKM). By 
contrast, levels of CMYA5 where significantly higher in skeletal muscle (388.3 RPKM) compared to heart (94.2 
RPKM). Interestingly, these data place CMYA5 (myospryn) in the top 100 most highly expressed transcripts in 
skeletal muscle. The relative abundance of each transcript is mirrored by the levels of the cognate protein in the 
same tissue (Fig. 2c)9.
Since paralogous proteins often participate in similar protein:protein interactions we used 
co-immunoprecipitation to determine whether minispryn and myospryn form a protein complex in vivo. 
Proteins were co-immunoprecipitated from heart and skeletal muscle RIPA extracts using myospryn- and 
minispryn-specific antibodies. Myospryn and minispryn were robustly immunoprecipitated with their cog-
nate antisera (Fig. 2d and e). Importantly, minispryn was detected in the protein complex immunoprecipi-
tated with anti-myospryn antisera. Conversely, myospryn was detected in material immunoprecipitated by the 
anti-minispryn antibody. In control experiments, neither myospryn nor minispryn could be immunoprecipitated 
from cardiac or skeletal muscle with an unrelated IgG (Fig. 2d and e).
Figure 1. Minispryn bioinformatics. (a) Domain architecture of minispryn and related proteins. Minispryn, 
myospryn and two members of the TRIM-protein family share extensive sequence similarity at their C-termini. 
While the TRIM proteins are E3 ubiquitin ligases, the absence of the RING domain in minispryn and myospryn 
probably preclude this function. (b) Multiple sequence alignment. The complete coding sequence of minispryn 
aligns with amino acids 3171–3739 of myospryn (CAE02649.1), 139–706 of midline-1 (XP_017173902) and 
123–366 of murf3 (NP_067422.1) spanning the BBOX/BBOX’ and BBC domains of each protein and the FN3 
and SPRY domains of myospryn and midline-1.
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Immunoaffinity purification of the myospryn complex from cardiac muscle. To search for addi-
tional minispryn:myospryn associated proteins, we used the 819 antibody to immunoaffinity purify minispryn 
and associated proteins from mouse heart. Immunoprecipitated proteins were eluted from the immunoaffinity 
matrix and resolved on Novex gradient gels stained with colloidal Coomassie blue (Fig. 3a). Minispryn (band 
A3) was highly enriched following immunoaffinity purification demonstrating the efficacy of this technique for 
protein purification from tissue (Fig. 3b). Bands that were not shared with the protein G control were excised 
Figure 2. Minispryn transcript and protein. (a) Northern blot showing the size and tissue distribution of 
the murine minispryn transcript. A single band of approximately 7 kb is only detected in heart and skeletal 
muscle. The blot was stripped and re-hybridized with a GAPDH probe to demonstrate the presence of mRNA 
in each lane. Key: B, brain; H, heart; Lu, lung; Li, liver; Ki, kidney; St, stomach; SI, small intestine; M, muscle; 
O, ovary; Th, thymus; Te, testes; U, uterus; PU, pregnant uterus; Pl, placenta; Sp, spleen. (b) Western blot of 
several mouse tissues showing that minispryn is a protein of approximately 90 kDa that is found predominantly 
in heart and skeletal muscle. (c) Antibody specificities were determined in heterologous cells. Lysates prepared 
from HEK-293T cells expressing full-length myospryn (clone 21B) and minispryn (clone 7E) were processed 
for immunoblotting with antibodies detecting their cognate antigen. The 819 antibody only detects minispryn 
in transfected cells whereas des122 only detects myospryn under the same conditions. The lysates were also 
immunoblotted with anti-tubulin antibodies to demonstrate similar levels of protein in each transfection. 
Lysates prepared from untransfected HEK-293T cells are also shown. (d) In tissue, minispryn and myospryn 
were immunoprecipitated from RIPA extracts of cardiac muscle using specific antibodies. Minispryn and 
myospryn are robustly immunoprecipitated with their cognate antisera but also co-IP with the antisera raised 
against the paralogous protein. Neither myospryn nor minispryn are immunoprecipitated with unrelated IgG. 
(e) Minispryn and myospryn similarly co-immunoprecipitate from RIPA extracts of skeletal muscle. X denotes 
an empty lane.
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from the gel, digested with trypsin and analysed by mass spectrometry. Tryptic peptides derived from minispryn 
(band A3) and myospryn (band A1 and A2) were readily identified, supporting our finding that both proteins 
exist in a complex in vivo (Table 1). Furthermore, numerous peptides corresponding to the cardiac ryanodine 
receptor (RyR2) were obtained from band A1 at approximately 550 kDa. Although SERCA2 was also identi-
fied in band A3, we have not confirmed this potential interaction experimentally (Fig. 3a). In control experi-
ments, myospryn was immunoaffinity purified from cardiac muscle using des122-conjugated agarose beads 
(Supplementary Fig. S4). Once again, bands were excised and processed for mass spectrometry as described 
above. Tryptic peptides derived from myospryn, minispryn and RyR2 were identified in the myospryn immuno-
affinity purification (Supplementary Dataset 1). Interestingly, previously described interactors such as α-actinin 
did not co-purify with myospryn under the conditions used to immunoaffinity purify the complex from cardiac 
muscle (Supplementary Fig. S4)10.
Immunolocalisation of myospryn in striated muscle. Confocal microscopy was used to localise myos-
pryn and minispryn in isolated adult guinea pig ventricular cardiomyocytes. At low magnification, myospryn 
Figure 3. Immunoaffinity purification of the myospryn complex from cardiac muscle. (a) Proteins eluted from 
an anti-minispryn immunoaffinity column or protein G only column were separated by PAGE and stained with 
colloidal Coomassie blue dye. Bands A1-A3 that were only present in minispryn immunoaffinity eluate were 
excised and processed for mass spectrometry. The identity of the major protein(s) found in each band is listed. 
Note that in this study we focussed exclusively on proteins in bands A1, A2 and A3. Corresponding peptides 
for myospryn, RyR2 and minispryn are shown in Supplementary Dataset 1. (b) Robust minispryn enrichment 
following immunoaffinity purification was demonstrated by immunoblotting using the 819 anti-minispryn 
antibody. The sizes of the molecular weight markers are shown in kDa.
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immunoreactivity was concentrated in discontinuous stripes that ran tangentially to the long axis of the cardio-
myocyte (Fig. 4a and d). Myospryn immunoreactivity was also present diffusely throughout the myocyte and also 
in or around the nucleus as described previously (arrow in Fig. 4a)21. A similar pattern of immunoreactivity was 
found with the anti-RyR antibody within the same cell suggesting that myospryn is localised to the sarcoplasmic 
reticulum (SR) of cardiomyocytes (Fig. 4b). At higher magnification, myospryn and the RyRs co-localise in distinct 
punctae throughout the cell (Fig. 4d–f). Similarly, minispryn immunoreactivity was detected in discontinuous stri-
ations running perpendicular to the long axis of the cardiomyocyte that partially co-localise with RyR2 (Fig. 4g–j). 
Punctate myospryn immunoreactivity also overlapped with the continuous α-actinin labelling at the Z-line of the 
cardiomyocyte (Fig. 4m–o). Minispryn immunoreactivity also overlapped α-actinin at the Z-line (Fig. 4p–r) and 
despite the absence of an apparent nuclear localisation signal, minispryn was also found in or around the nucleus 
(arrow in Fig. 4g and p). Double labelling with antibodies raised against SERCA2 (Fig. 4s–u) or sarcalumenin 
(Fig. 4v–x) showed that myospryn is associated with the junctional SR (j-SR) rather than the majority of the longi-
tudinal SR (l-SR) that also contain SERCA2 and sarcalumenin (Fig. 4s–x).
We also examined the subcellular localisation of myospryn and minispryn in skeletal muscle using antibodies 
that label different compartments of the myocyte (Supplementary Fig. S6). In longitudinal sections of guinea pig 
quadriceps muscle, minispryn is localised to a region flanking the Z-line, labelled with an anti-α-actinin anti-
body (Supplementary Fig. S6). No labelling of the sarcolemma was observed. By contrast to α-actinin labelling, 
minispryn immunoreactivity is concentrated in small punctae that run parallel to the Z-line. This pattern is 
reminiscent of the sarcoplasmic reticulum as shown by double immunofluorescence labelling of minispryn and 
the RyRs in the same section. Both antigens have a similar and partially overlapping distribution in longitudinal 
sections suggesting that minispryn also concentrates at the SR. In skeletal muscle myospryn (and minispryn) 
punctate immunoreactivity is observed flanking the Z-line (at the A-I band interface) in close apposition to RyRs 
whereas in cardiomyocytes, the terminal cisternae of the SR are localised directly above the Z-line in fixed and 
live cardiomyocytes (Fig. 4 and Supplementary Fig. S6)29. Thus, the differences in myospryn immunolocalisation 
between cardiac and skeletal muscle are consistent with the differential geometry of the SR characteristic of the 
two types of striated muscle30, 31.
Myospryn clusters RyR2 in heterologous cells. To explore the functional significance of the associa-
tion between myospryn, minispryn and RyR2, we expressed different combinations of each cDNA in COS-7 cells. 
In transfected cells expressing only one construct, we found that full length myospryn and minispryn were distrib-
uted throughout the cytoplasm of the cell and appeared to associate with intracellular membranes (Fig. 5a and c). 
We also observed that minispryn immunoreactivity was found in the nucleus whereas myospryn was apparently 
excluded. By contrast, RyR2 was found in the endoplasmic reticulum as expected (Fig. 5b). It is noteworthy that 
endogenous myospryn, minispryn and RyR2 were not detected in COS-7 cells with the antibodies used in this 
study. Co-expression of myospryn with RyR2 caused the dramatic relocalisation of both proteins into intensely 
staining punctae (Fig. 5d–f). By contrast, co-expression of minispryn with RyR2 had no apparent effect on the 
localisation of either protein (Fig. 5g–i). Co-expression of myospryn and minispryn in COS7 cells does not appear 
to cause the redistribution of either protein. We also used a range of truncated myospryn constructs to map the 
region of the protein that clusters RyR29, 25. MD7 (amino acids 3039–3739) that contains the BBOX’, BBC, FN3 and 
SPRY domains was unable to cluster RyR2. By contrast, the larger construct MD9 (amino acids 2731–3739) that 
contains all of the aforementioned C-terminal domains and an additional contiguous 311 amino acids efficiently 
clusters RyR2 in cells expressing both constructs (Fig. 5j–l). These data indicate that a conserved region encom-
passing amino acids 2731–3041 of mouse myospryn is likely to be required for RyR2 clustering. Interestingly, this 
region is not found in minispryn because the region of sequence similarity only extends from amino acids 3179 to 
3736 of myospryn9. Furthermore, the RyR2-clustering region of myospryn is in an evolutionarily conserved region 
of the protein that is distinct from the other ligand binding sites in the TRIM-like domain15, 26.
Protein Score Coverage Peptides MW
MINISPRYN IAP
ryanodine receptor 2, cardiac [Mus musculus]/
gi124430578 (A1) 1496.39 24.16 120 564.5
stretch-responsive fibronectin protein type 3 [Mus 
musculus]/gi45774102 (A1) 1458.93 34.30 110 397.5
fibronectin type III and SPRY domain-containing 
protein 2 [Mus musculus]/gi116063550 (A3) 432.45 36.31 31 81.4
MYOSPRYN IAP
ryanodine receptor 2, cardiac [Mus musculus]/
gi124430578 3427.78 36.57 246 564.5
stretch-responsive fibronectin protein type 3 [Mus 
musculus]/gi45774102 3008.80 42.70 188 397.5
fibronectin type III and SPRY domain-containing 
protein 2 [Mus musculus]/gi116063550 463.66 36.73 58 81.4
Table 1. Mass spectrometry statistics for minispryn and myospryn immunoaffinity purification from mouse 
heart. Proteins identified by mass spectrometry from minispryn (Fig. 3a) and myospryn (Supplementary 
Fig. S4) immunoaffinity purification from cardiac muscle. For clarity, in this study we have only focussed on 
the three most significant matches from each experiment. Note that stretch-responsive fibronectin protein type 
3 [Mus musculus]/gi45774102 is the alternative name for Cmya5/myospryn and fibronectin type III and SPRY 
domain-containing protein 2 [Mus musculus]/gi116063550 is Fsd2/minispryn.
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Discussion
The cytoarchitecture of striated muscle is governed in part by the assembly of macromolecular protein complexes 
that form connections between the myofilaments in the sarcomere and sarcolemma of the myocyte. In order 
to do this, the myocyte produces a number of unusually large modular proteins that integrate mechanical and 
signalling processes throughout the cell7, 8. Electrical excitation of the myocyte leads, via Ca2+-signalling, to acti-
vation of the myofilament and contraction. Electrical activity is propagated throughout the myocyte by branched 
invaginations of the sarcolemma known as transverse tubules (t-tubules) that form a highly connected network 
of tubules that surround myofilaments32. T-tubules are involved in EC-coupling by concentrating voltage-gated 
Ca2+ channels (VGCC) such as the dihydropyridine receptor in close proximity to the RyRs in the j-SR33. The pre-
cise juxtaposition of the VGCC with Ca2+-releasing RyRs ensures tight coupling between electrical activity and 
Ca2+-signalling at so-called couplons; dyads in cardiac muscle and triads in skeletal muscle34–36. Myospryn, one 
the largest proteins in striated muscle, has been ascribed a number of structural and signalling functions medi-
ated by interactions with different components of the myocyte15, 26. In this paper, we have used immunoaffinity 
purification and mass spectrometry to show that myospryn is part of a multiprotein complex in cardiac muscle 
that contains a novel myospryn paralog, minispryn and the cardiac ryanodine receptor, RyR2.
To gain further insight into the role of minispryn and myospryn we use a panel of antibodies to immuno-
affinity purify each protein directly from cardiac and skeletal muscle. Using a combination of mass spectrometry 
and western blotting, we show that myospryn and minispryn co-immunoprecipitate from both tissues and are 
found in a complex with RyR2 in cardiac muscle (Fig. 3a). Importantly, these data were also confirmed when 
RyRs were immunoaffinity-purified from heart using the well-characterised pan-RyR antibody, 34C37. It is also 
Figure 4. Immunolocalization of myospryn and minispryn in isolated cardiomyocytes. Enzymatically isolated 
guinea pig ventricular cardiomyocytes were fixed and processed for confocal immunofluorescence microscopy 
using the indicated antibodies. (a–c) At low magnification myospryn (a) immunoreactivity is visible in 
discontinuous striations that run perpendicular to the long axis of the cardiomyocyte partially overlapping 
the nucleus (arrow in a). (d–f) Higher magnification images show that myospryn immunoreactivity is present 
in distinct punctae that co-localise with ryanodine receptors (e) in the SR (f and inset). (g–i) Anti-minispryn 
(g) immunoreactivity also appears in discontinuous striations running the length of the cardiomyocyte and is 
also present in the nucleus (arrow in g). (j–l) In common with myospryn, higher magnification images show 
that minispryn partially co-localises with ryanodine receptors (k) in the SR (l and inset). (m–o) Myospryn 
immunoreactivity overlaps the Z-line labelled with an anti-alpha-actinin antibody (m, n, o). (p–r) Similarly, 
minispryn immunoreactivity also partially overlaps alpha-actinin at the Z-line (p, q, r). (s–x) Cardiomyocytes 
labelled with either anti-SERCA2 (s, t, u) or anti-sarcalumenin (v, w, x) antibodies and myospryn antibodies 
demonstrate that myospryn immunoreactivity (arrowheads in s) appears to be restricted to the j-SR rather than 
the l-SR (arrows in t).
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Figure 5. Myospryn clusters RyR2 in heterologous cells. COS-7 cells were transfected with expression 
constructs as indicated. (a–c) Full-length myospryn (a) and minispryn (c) appear to be associated with the 
internal membranes of the cell when expressed on their own whereas RyR2 (b) labelling is restricted to the 
endoplasmic reticulum. (d–f) Co-expression of myospryn (d) and RyR2 (e) results in the clustering of both 
proteins in intensely staining punctae (merged image, f). Note that myospryn is not clustered in the adjacent cell 
(asterisk) that does express RyR2. (g–i) By contrast co-expression of minispryn (g) and RyR2 (h) does not alter 
the distribution of either protein (merged image, i). (j–o) Truncated myospryn constructs were used to delineate 
the regions of the protein involved in RyR2 clustering. MD9 (j) was able to cluster RyR2 (k and merged image, 
l) whereas the smaller protein MD7 (m) failed to cluster the receptor (n and merged image, o). The underlining 
denotes the transfected construct for each channel. Scale bar = 10 µm.
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noteworthy that the myospryn interactors, PKA, RIIα and calcineurin have all been shown to interact with 
RyR238, 39. Furthermore, myospryn and minispryn co-localise with RyRs in isolated adult ventricular cardiomyo-
cytes (Fig. 4). Since myospryn and minispryn lack predicted transmembrane domains, our data suggest that the 
myospryn complex is concentrated at dyad couplons in cardiac muscle. Similarly, myospryn and minispryn also 
co-localise with skeletal muscle RyRs at the j-SR (Supplementary Fig. S6). In common with cardiac muscle, the 
SR of striated muscle can be divided into two sub-domains; the j-SR or triad couplon formed between the t-tubule 
and terminal cisternae of the SR and the l-SR30, 31, 35, 40.
To our surprise, we found that myospryn was able to cluster RyR2 in heterologous cells (Fig. 5). Conserved 
regions in the C-terminus of myospryn that are not present in minispryn mediated RyR2 clustering. To the best 
of our knowledge this is the first example of a protein that can actively cluster RyRs. However, in striated muscle 
it is also possible that myospryn promotes the apparent clustering of RyRs by altering the structure of the SR. It is 
therefore tempting to speculate that one function of the myospryn complex in cardiac muscle is in the formation 
and maintenance of RyR clusters. Although it is clear that RyR clustering is essential for EC coupling, little is 
known about the processes driving receptor aggregation and the role of components of the couplon in this pro-
cess41. Expression of RyRs in heterologous cells results in distribution of the protein throughout the ER. Indeed, 
biophysical studies on the inositol 1,4,5-trisphosphate receptor (IP3R) and RyR1 expressed in COS7 cells show 
both proteins have similar diffusion rates in the endoplasmic reticulum indicative of free movement through the 
subcellular domain42. By contrast, RyRs extracted from skeletal muscle and heart tissue can self-associate into 
discrete, higher order configurations43, 44.
Weakened calcium transients mediated by RyRs are one of the major pathological features underlying heart 
failure. Although there are well documented differences between the SR structure in skeletal and cardiac muscle, 
the maintenance of RyR clusters appears to be essential for physiological EC-coupling45. Maladaptive t-tubule 
remodelling in heart failure and hypertrophic cardiomyopathy leads to abnormalities in Ca2+-signalling associ-
ated with orphaned RyRs46–48. Orphaned RyRs appear to be spatially distinct having lost their couplings with the 
DHPRs in the t-tubule system. Recently, two-photon microscopy has shown that defects in t-tubular electrical 
activity are responsible for the abnormalities in Ca2+-signalling observed in different animal models of heart fail-
ure and hypertrophic cardiomyopathy49, 50. It would therefore be important to determine whether the myospryn 
complex is involved in the uncoupling of RyRs in different models of heart failure and cardiomyopathy.
It is well established that adult ventricular cardiomyocytes dedifferentiate in culture resulting in the dramatic 
loss of t-tubules, effectively precluding their use for acute knockdown experiments aim at studying the function 
of the myospryn complex ex vivo51, 52. However, the physiological role of the myospryn complex in striated mus-
cle could be determined using transgenic animals with mutations in Cmya5 and Fsd2. If viable, RyR2 clustering 
and SR function in cardiomyocytes lacking myospryn and minispryn could be determined using state of the art 
imaging techniques as described recently49. Similarly, high resolution imaging and electron microscopy could be 
used to examine the association of the myospryn complex with other components of the cardiomyocyte using a 
panel of antibodies53–55. This may be particularly informative because most of the antibodies developed to date 
have been generated against epitopes in the extreme C-terminus of myospryn9, 21, 25. It is therefore possible that 
other regions of a conserved large protein like myospryn can interact with different subcellular components of 
the cardiomyocyte.
It is tempting to speculate that differential expression of CMYA5 in cardiomyopathies and muscular dystrophy 
may contribute to the disease process through physical interactions with RyRs that affect their clustering or asso-
ciation with other proteins in the couplon. It is noteworthy that alterations in the post-transcriptional and trans-
lational regulation of the genes encoding numerous SR components converging on RyR2 have been documented 
in heart failure56. Interestingly, a common polymorphism in CMYA5 (K2906N) has also been associated with left 
ventricular wall thickness in patients with hypertension17. This polymorphism is immediately proximal to the 
evolutionary conserved region in myospryn that is required for RyR2 clustering (Fig. 5). In addition, CMYA5 
and RYR2 mutations have recently been found in patients with hypertrophic cardiomyopathy18. Whether these 
CMYA5 and RYR2 mutations are pathogenic or merely rare polymorphisms remains to be determined through 
replication in larger samples. Taken together, our data suggest a novel role for the myospryn complex in diseases 
of cardiac and skeletal muscle that is potentially mediated through interactions with protein components of the 
couplon. Our data provide a possible molecular basis for previous observational studies suggesting a role for 
myospryn in cardiomyopathy, muscle hypertrophy and muscular dystrophy13–16.
Methods
Molecular Biology. A 2.2 kb PCR product spanning the srf30 EST that encodes the BBOX’ domain 
of a hitherto unknown cDNA9 was produced from muscle first strand cDNAs using the primers, 
5′-GACTCAGAACATCCACTGACTGAG and 5′-GGAAATACCAAAAGGGCCTAAAAG. This product was 
radiolabelled with 32P-dCTP and used to screen a murine adult muscle cDNA library constructed in pPC86 
(Invitrogen) using standard methodology. Several positively-hybridising cDNA clones were identified and 
end-sequenced. The complete sequence of the longest cDNA clone, mini7E, was obtained. The entire open read-
ing frame of minispryn was amplified by PCR with the primers 5′-GTCGACATGAGAGAGGAAGCAGAGGAG 
and 5′-GGATCCCTAAAAGAAAGTGACATGCTTTGG and cloned into the SalI/BamHI sites of pEGFP-C1 
(Clontech) and fully sequenced to produce GFP-minispryn. Expression constructs encoding the C-terminus of 
myospryn (clone MD9 and MD7) and full length myospryn (clone c21B) have been described previously9. The 
murine RyR2 construct (mRyR2) was kindly supplied by Dr S. Wayne Chen57. Sequence alignments were per-
formed using PILEUP (GCG version 10) and shaded with BOXSHADE (http://www.ch.embnet.org/software/
BOX_form.html). Domains in myospryn and minispryn were identified using the program SMART (http://
smart.embl-heidelberg.de/)58.
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Antibodies. Rabbit polyclonal antisera were raised against minispryn as follows. A PCR prod-
uct encoding amino acids 1 to 227 of minispryn was produced by PCR using the primers, 
5′-TGAATTCATGGAGGAGGAAGCAGAG and 5′-TGTCGACTCAATTGTAATGGCACTCAAAGTTTT. This 
region of minispryn has no sequence similarity to myospryn minimising any potential cross-reactivity between 
antibodies raised against the two proteins. The resulting PCR product was cloned downstream of thioredoxin in 
pET32a (Novagen) to produce a chimeric fusion protein that was used to immunize New Zealand white rabbits. 
Anti-thioredoxin antibodies were removed by affinity purification on a Sulfolink (Pierce) thioredoxin column 
and the resulting anti-minispryn antibody (819) was affinity-purified against the cognate antigen coupled to 
Sulfolink. The des122 anti-myospryn antibody was raised against amino acids 2791 to 2913 of murine myospryn 
in rabbits as described previously 9. The anti-α-actinin monoclonal antibody, clone EA-53, was purchased from 
Sigma. The 34C (anti-ryanodine receptor) and XIIC4 (anti-sarcalumenin) monoclonal antibodies were obtained 
from the Developmental Studies Hybridoma Bank (Iowa)37. The anti-SERCA2 antibody (MA3-910) from was 
obtained from Affinity Bioreagents (Thermo Fisher Scientific).
Cell culture and transfection. COS-7 and HEK-293T cells were grown in Dulbecco’s modified Eagle’s 
medium (Sigma) supplemented with 10% (v/v) foetal calf serum, 100 µg/ml penicillin and 100 µg/ml strepto-
mycin at 37 °C in a 5% CO2 atmosphere. Transfections were performed using Fugene (Roche). Cells grown in 
6 cm diameter dishes were transfected with 1–2 µg of plasmid DNA for immunoprecipitation experiments. For 
immunocytochemistry, cells were grown on 22 mm coverslips and transfected with 0.5–1 µg of DNA. Cells were 
grown for 24 h after transfection. Enzymatically isolated adult guinea pig ventricular cardiomyocytes (GPVCs) 
were prepared as described previously59, 60. After isolation, the GPVCs were not maintained in culture but used 
directly for immunocytochemistry, as described below.
Immunoaffinity purification and mass spectrometry. Anti-myospryn (des122), -minispryn (819) and 
-RyR antibodies (34C) were covalently cross-linked to protein A/G-agarose as described previously61. Freshly 
dissected mouse hearts (500 mg) were homogenised in 12 ml RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 
1% (v/v), Triton X-100, 0.5% (w/v) sodium deoxycholate) containing EDTA-free protease inhibitors (Roche) 
using a Polytron homogeniser operated at full speed for 20 sec. The homogenate was incubated on ice for 30 min 
and clarified by centrifugation at 100,000 g for 30 min in an SW41Ti rotor (Beckman). The supernatant was 
pre-cleared with 200 µl of protein A (Invitrogen) for 3 h at 4 °C. The pre-cleared supernatant was split into two 
and 50 µl of protein-A/G antibody conjugate or unconjugated protein A/G was added to each sample. IgG com-
plexes were captured after overnight incubation at 4 °C on a blood mill by centrifugation, 1000 g for 5 min at 
4 °C. The flow-through from each experiment was retained and diluted 1:1 in lithium dodecyl sulphate sample 
(Invitrogen) buffer containing DTT. The beads were washed twice in 1 ml of RIPA buffer containing 0.5 M NaCl 
and eluted in 200 µl of lithium dodecyl sulphate sample buffer containing 50 mM DTT. 30 µl samples were sepa-
rated on 4–12% NuPAGE bis-TRIS gels (Invitrogen) run in MOPS/SDS running buffer (Invitrogen). Gels were 
fixed in 50% (v/v) methanol, 7% (v/v) acetic acid for 30 min, washed, stained with colloidal Coomassie blue stain 
(Gelcode Blue Stain Reagent, Pierce) for 2 h and destained in CHROMOSOLV Plus HPLC-grade water (Sigma) 
for 5 h. Coomassie-stained bands were manually excised and processed for mass spectrometry as described pre-
viously62. Briefly, proteins in the individual gel slices were digested with trypsin using a robotic gel handling sys-
tem (Functional Genomics, Proteomics and Metabolomics Facility, University of Birmingham). Tryptic peptides 
were fractionated by liquid chromatography and analysed on a Orbitrap Velos ETD mass spectrometer (Thermo 
Fisher). Database searches were performed using the Mascot and SEQUEST algorithms in Proteome Discoverer™ 
Software (ThermoFisher).
Immunocytochemistry. GPVCs were allowed to adhere to flamed coverslips for 30 min at room tempera-
ture, prior to fixation in 1 ml of 4% (w/v) paraformaldehyde in PBS at 4 °C for 15 min. Cells were permeabilised in 
0.1% (v/v) Triton X-100 in PBS by incubation for 15 min at 4 °C. Following permeabilisation, the coverslips were 
washed twice in 2 ml of PBS and blocked in 10% FCS (v/v) in PBS for 20 min at room temperature. GPVCs were 
incubated with the primary antibody for 1 h at room temperature, washed twice in PBS prior to incubation for a 
further hour with either Alexa Fluor 488-conjugated anti-mouse IgG or Alexa Fluor 568-conjugated anti-rabbit 
IgG (Thermo Fisher). Coverslips were washed twice more in PBS, rinsed in molecular biology grade water and 
mounted on glass slides using Vectashield mounting medium (Vector Laboratories). Images were captured using 
a Zeiss LSM 510META confocal microscope using a 63x oil immersion objective lens and a pinhole setting of 
1 Airy unit. Images were assembled using Adobe Photoshop CS4, in which they were cropped and adjusted for 
brightness and contrast, but not otherwise manipulated.
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